Abstract | BACKGROUND: METHODS: This study was a parallel, double-blind, randomized, three-arm (1:1:1), placebo-controlled study. Thirty-one subjects with PAR were enrolled and received double-blind medication: fexofenadine 120 or 180 mg, or placebo, once a day for 28 days. RESULTS: The total symptom score was reduced by fexofenadine (both dosages) at V2 (P=0.007), whereas placebo did not modify it. Nasal congestion decreased after 1 week of treatment with fexofenadine 120 (P=0.027) and 180 (P=0.01), but not with placebo (P=NS). At V3, fexofenadine (both dosages) significantly reduced nasal congestion (P=0.011 and P=0.007, respectively), by placebo did not show any significant effect. CONCLUSIONS: This pilot study represents the first evidence of the efficacy of fexofenadine in PAR, and also the control of the nasal congestion. We suggest performing larger trials to confirm these preliminary findings.
|
Authors | G Ciprandi, C Cosentino, M Milanese, C Mondino, G W Canonica |
Journal | Allergy
(Allergy)
Vol. 56
Issue 11
Pg. 1068-70
(Nov 2001)
ISSN: 0105-4538 [Print] Denmark |
PMID | 11703220
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Histamine H1 Antagonists
- Terfenadine
- fexofenadine
|
Topics |
- Adolescent
- Adult
- Animals
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Histamine H1 Antagonists
(administration & dosage, therapeutic use)
- Humans
- Male
- Middle Aged
- Mites
- Nasal Mucosa
(drug effects)
- Pilot Projects
- Rhinitis, Allergic, Perennial
(drug therapy, etiology)
- Sneezing
(drug effects)
- Terfenadine
(administration & dosage, analogs & derivatives, therapeutic use)
- Treatment Outcome
|